CILOXAN (ciprofloxacin hydrochloride) by Novartis is clinical pharmacology systemic absorption a systemic absorption study was performed in which ciprofloxacin ophthalmic solution was administered in each eye every two hours while awake for two days followed by every four hours while awake for an additional 5 days. Approved for mycobacterium avium complex infection, hiv infections. First approved in 1990.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
CILOXAN is a fluoroquinolone antibiotic ophthalmic solution containing ciprofloxacin hydrochloride. It treats bacterial eye infections by inhibiting DNA gyrase, a bacterial enzyme essential for DNA synthesis. The drug is bactericidal against a broad spectrum of gram-positive and gram-negative organisms with minimal systemic absorption.
Product is approaching loss of exclusivity with modest Part D spending of $1M and 5,169 claims in 2023, indicating a mature established product with a small stable team.
CLINICAL PHARMACOLOGY Systemic Absorption A systemic absorption study was performed in which ciprofloxacin ophthalmic solution was administered in each eye every two hours while awake for two days followed by every four hours while awake for an additional 5 days. The maximum reported plasma…
Worked on CILOXAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCILOXAN currently shows zero linked job postings, reflecting its mature, established status with minimal hiring activity. Career opportunities on this product are limited to maintenance commercial operations and regulatory support roles.